Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HemoBioTech has received an exclusive worldwide license from Texas Tech University System for a new technology that addresses the safety of animal-derived products for human use in pharmaceutical, cosmetic and other industries.
Subscribe to our email newsletter
The technology is being used in the manufacturing of HemoBioTech’s lead product HemoTech, potentially the first viable substitute for human blood. HemoTech is composed of chemically modified bovine hemoglobin.
The new purification technology could allow robust and reliable elimination of infectious agents, such as prions and viruses from the final product, using independent clearance steps, inactivation and removal. The FDA strictly regulates medicinal products and cosmetics that contain ingredients from animals, particularly of bovine origin.
Arthur Bollon, chairman and CEO of HemoBioTech, said: “The goal is not only to use it for the manufacturing of our HemoTech but also to sublicense it to pharmaceutical, biotech, cosmetic and other companies that use animal-derived products for a variety of human uses. There is a continuing need to optimize the safety of such products for human use.”